Meta-analysis finds bright light therapy boosts remission and response in nonseasonal depression, offering a low-cost add-on to standard care.
|Videos|July 22, 2021
Paving a Path Forward to Overcome Stigma
Author(s)Shahla Modir, MD
A recent All Points North Lodge survey found 37% of Americans are comfortable discussing mental health, but 44.7% have never tried counseling. What is preventing them from seeking care?
Advertisement
Despite the difficult past 2 years, negative views of mental health persist. Shahla Modir, MD, discusses the results of the
To see more from this survey, check out
Dr Modir is the Chief Medical Officer at All Points North Lodge and the Chief Psychiatrist at Avalon Malibu, Summit Malibu.
Advertisement
Related to this article
Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.
Teacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.
The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.
Oveporexton (Orzeyful) is now available in the US by prescription for the treatment of narcolepsy type 1.
Explore the types of scams encountered in psychiatric practice in order to help identify those at risk.
Mixed-feature depression can signal bipolar risk; spot red flags and consider lurasidone or lumateperone before standard antidepressants.
Explore how OCD and schizophrenia overlap, complicating diagnosis and care, and learn spectrum-based strategies and treatment pitfalls for managing schizo-obsessive symptoms.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Shelves Fast-Track Drug Review Initiative
2
Oveporexton Now Available: First and Only Orexin Agonist for Narcolepsy Type 1
3
Schizo-Obsessed! Untangling the Overlap Between Obsessive Compulsive Disorder and Schizophrenia
4
Scams: What Psychiatrists Need to Know
5